(Q45771233)

15 December 2017

title

Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National Cohort Study (English)

1 reference

15 December 2017

author name string

L Stojanovich

1

1 reference

15 December 2017

O Markovic

2

1 reference

15 December 2017

D Marisavljevic

3

1 reference

15 December 2017

I Elezovic

4

1 reference

15 December 2017

N Ilijevski

5

1 reference

15 December 2017

N Stanisavljevic

6

1 reference

15 December 2017

publication date

12 October 2011

1 reference

15 December 2017

published in

Lupus

1 reference

15 December 2017

volume

21

1 reference

15 December 2017

issue

3

1 reference

15 December 2017

page(s)

338-345

1 reference

15 December 2017

Antiphospholipid syndrome

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Clinical and laboratory features of the catastrophic antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Which are the best biological markers of the antiphospholipid syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Antiphospholipid syndrome in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Clinical and immunological features in 112 patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Migraine, memory loss, and "multiple sclerosis ". Neurological features of the antiphospholipid (Hughes') syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Pulmonary manifestations in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Ocular manifestations in antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

The antiphospholipid syndrome: ten years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Diagnosis of antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Central nervous system involvement in the antiphospholipid (Hughes) syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203311422710

21 January 2018

Identifiers

DOI

10.1177/0961203311422710

1 reference

15 December 2017

1 reference

15 December 2017